

**Table S8.** Baseline characteristics of all tofacitinib-treated and tocilizumab-treated RA patients in the cohort, grouped by the status of previous bDMARD use, before IPTW adjustment

	bDMARD-naïve patients (n = 274)			Previous bDMARD-experienced patients <sup>†</sup> (n = 329)		
	Tofacitinib (n = 100)	Tocilizumab (n = 174)	ASD*	Tofacitinib (n = 201)	Tocilizumab (n = 128)	ASD*
Age, years, mean (SD)	64.4 (13.6)	66.1 (12.8)	0.13	67.1 (11.3)	63.4 (12.4)	0.31
Male sex, number (%)	22 (22.0)	52 (29.9)	0.18	45 (22.4)	28 (21.9)	0.012
RA duration, years, mean (SD)	9.2 (11.2)	7.8 (8.6)	0.14	13.8 (9.5)	11.2 (9.3)	0.28
Advanced stage <sup>‡</sup> , number (%)	34 (34.0)	56 (32.2)	0.040	121 (60.2)	66 (51.6)	0.17
Anti-CCP-positive, number (%)	84 (84.0)	143 (82.2)	0.050	177 (88.1)	111 (86.7)	0.040
RF-positive, number (%)	87 (87.0)	143 (82.2)	0.13	171 (85.1)	109 (85.2)	0.002
CDAI, mean (SD)	22.8 (9.4)	23.7 (10.1)	0.090	22.7 (10.3)	22.5 (10.2)	0.028
Previous MTX failure, number (%)	92 (92.0)	122 (70.1)	0.58	181 (90.0)	117 (91.4)	0.047
Previous bDMARD failure <sup>†</sup> , number (%)	0	0	–	168 (83.6)	105 (82.0)	0.041
Concurrent MTX use, number (%)	62 (62.0)	82 (47.1)	0.30	106 (52.7)	78 (60.9)	0.17
Concurrent PSL use, number (%)	28 (28.0)	87 (50.0)	0.46	53 (26.4)	58 (45.3)	0.40

\*Balance in each of the baseline characteristics was examined between the tofacitinib and tocilizumab groups, separately in bDMARD-naïve patients and bDMARD-experienced patients. ASD of <0.1 indicates that the baseline characteristic was well balanced between the two treatment groups.

<sup>†</sup>Previous bDMARD-experienced patients were defined as those who had previously discontinued bDMARD therapy due to intolerance or lack/loss of efficacy.

Previous bDMARD failure was defined as previous discontinuation of bDMARD therapy due to lack or loss of efficacy.

<sup>‡</sup>Advanced stage was defined as Steinbrocker radiological stages III and IV.

RA, rheumatoid arthritis; bDMARD, biological disease-modifying antirheumatic drug; anti-CCP, anti-cyclic citrullinated peptide antibodies; RF, rheumatoid factor; MTX, methotrexate; PSL, prednisolone; CDAI, clinical disease activity index; SD, standard deviation; ASD: absolute standardized

difference